Literature DB >> 18594331

EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.

Jenifer L Marks, Ben Golas, Tomas Kirchoff, Vincent A Miller, Gregory J Riely, Kenneth Offit, William Pao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18594331     DOI： 10.1097/JTO.0b013e31817e4664

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

1.  EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Authors:  Heike N Pfäffle; Meng Wang; Liliana Gheorghiu; Natalie Ferraiolo; Patricia Greninger; Kerstin Borgmann; Jeffrey Settleman; Cyril H Benes; Lecia V Sequist; Lee Zou; Henning Willers
Journal:  Cancer Res       Date:  2013-08-21       Impact factor: 12.701

2.  Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.

Authors:  Annapaola Mariniello; Eleonora Ghisoni; Luisella Righi; Annamaria Catino; Rita Chiari; Alessandro Del Conte; Fausto Barbieri; Fabiana Cecere; Alain Gelibter; Matteo Giajlevra; Hector Soto Parra; Clizia Zichi; Massimo DI Maio; Giorgio Valabrega; Silvia Novello
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

Review 3.  Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.

Authors:  Ciara C O'Sullivan; Dominic H Moon; Elise C Kohn; Jung-Min Lee
Journal:  Front Oncol       Date:  2014-02-28       Impact factor: 6.244

Review 4.  "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.

Authors:  Lorena Incorvaia; Francesc Passiglia; Sergio Rizzo; Antonio Galvano; Angela Listì; Nadia Barraco; Rossella Maragliano; Valentina Calò; Clara Natoli; Marcello Ciaccio; Viviana Bazan; Antonio Russo
Journal:  Oncotarget       Date:  2017-04-04

5.  Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.

Authors:  Susana Cedrés; Enriqueta Felip; Cristina Cruz; Ana Martinez de Castro; Nuria Pardo; Alejandro Navarro; Alex Martinez-Marti; Jordin Remon; Jorge Zeron-Medina; Judith Balmaña; Alba Llop-Guevara; Josep M Miquel; Irene Sansano; Paolo Nuciforo; Francesco Mancuso; Violeta Serra; Ana Vivancos
Journal:  J Natl Cancer Inst       Date:  2018-08-01       Impact factor: 13.506

Review 6.  Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review.

Authors:  Yue I Cheng; Yun Cui Gan; Dan Liu; Michael P A Davies; Wei Min Li; John K Field
Journal:  BMC Cancer       Date:  2019-11-08       Impact factor: 4.430

Review 7.  Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.

Authors:  Luis Paz-Ares; Denis Soulières; Ivan Melezínek; Joachim Moecks; Lorenz Keil; Tony Mok; Rafael Rosell; Barbara Klughammer
Journal:  J Cell Mol Med       Date:  2009-12-08       Impact factor: 5.310

8.  Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.

Authors:  Jingrui Jiang; Alexei Protopopov; Ruobai Sun; Stephen Lyle; Meaghan Russell
Journal:  J Pers Med       Date:  2018-04-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.